SIETES :: 92466 citas

Resultados de la búsqueda por CARDIOVASCULARES REFINAR BÚSQUEDA

1.

El Zahran T, Schier J, Glidden E, Kieszak S, Law R, Bottei E, Aaron C, King A, Chang A. Characteristics of tianeptine exposures reported to the National Poison Data System — United States, 2000–2017. Morbidity and Mortality Weekly Report 2018;67:3 de agosto. [Ref.ID 102752]

2.

Anónimo. Public Citizen asks FDA to take gout drug off market due to cardiovascular risks. DIA Daily 2018:5. [Ref.ID 102701]

3.

Pasternak B, Inghammar M, Svanström H. Fluoroquinolone use and risk of aortic aneurysm and dissection: nationwide cohort study. BMJ 2018;360:8 de marzo. [Ref.ID 102640]

4.

Tsourdi E, Rachner TD, Hofbauer LC. Romosozumab versus alendronate and fracture risk in women with osteoporosis. N Engl J Med 2018;378:11 de enero. [Ref.ID 102629]

5.

Lewis JR, Schousboe JT, Prince RL. Romosozumab versus alendronate and fracture risk in women with osteoporosis. N Engl J Med 2018;378:11 de enero. [Ref.ID 102628]

6.

Song GG, Lee YH. Romosozumab versus alendronate and fracture risk in women with osteoporosis. N Engl J Med 2018;378:11 de enero. [Ref.ID 102627]

7.

Anónimo. Atezolizumab: Myocarditis. Canada. WHO Drug Information 2018;32:19. [Ref.ID 102622]

8.

Gershon AS, Campitelli MA, Hawken S, Victor C, Sproule BA, Kurdyak P, Selby P. Cardiovascular and neuropsychiatric events after varenicline use for smoking cessation. Am J Respir Crit Care Med 2018;197:913-22. [Ref.ID 102579]

9.

Elia J. Celecoxib gets partial exoneration from FDA panels. Physician's First Watch 2018:26 de abril. [Ref.ID 102574]

10.

Patorno E, Goldfine AB, Schneeweiss S, Everett BM, Glynn RJ, Liu J, Kim SC. Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study. BMJ 2018;360:6 de febrero. [Ref.ID 102541]

11.

Bally M, Beauchamp M-E, Abrahamowicz M, Nadeau L, Brophy JM. Risk of acute myocardial infarction with real-world NSAIDs depends on dose and timing of exposure. Pharmacoepidemiol Drug Saf 2018;27:69-77. [Ref.ID 102531]

12.

Wang M-T, Liou J-T, Lin CW, Tsai C-L, Wang Y-H, Hsu Y-J, Lai J-H. Association of cardiovascular risk with inhaled long-acting bronchodilators in patients with chronic obstructive pulmonary disease. A nested case-control study. JAMA Intern Med 2018;178:febrero. [Ref.ID 102529]

13.

Zheng SL, Roddick AJ, Aghar-Jaffar R, Shun-Shin MJ, Francis D, Oliver N, Meeran K. Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: a systematic review and meta-analysis. JAMA 2018;319:17 de abril. [Ref.ID 102513]

14.

Benefits NL, Pipe A, West R, Hays JT, Tonstad S, McRae T, Lawrence D, St Aubin L, Anthenelli RM. Cardiovascular safety of varenicline, bupropion, and nicotine patch in smokers. A randomized clinical trial. JAMA Intern Med 2018;178:622-31. [Ref.ID 102506]

15.

White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A, Hunt B, Castillo M, Gunawardhana L, for the CARES Investigators. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med 2018;378:29 de marzo. [Ref.ID 102489]

16.

Anónimo. Many lawsuits concerning diabetes drug saxagliptin transferred to US district judge in Kentucky. DIA Daily 2018:5. [Ref.ID 102461]

17.

Anónimo. Whistleblower lawsuit claims AstraZeneca knew of deadly risk of drug interaction. DIA Daily 2017:13. [Ref.ID 102162]

18.

Poole R, Kennedy OJ, Roderick P, Fallowfield JA, Hayes PC, Parkes J. Coffee consumption and health: umbrella review of meta-analyses of multiple health outcomes. BMJ 2017;359:j5024. [Ref.ID 102147]

19.

Anónimo. FDA to evaluate increased risk of heart -related death and death from all causes with the gout medicine febuxostat (Uloric). FDA U.S. Food and Drug Administration 2017:15 de noviembre. [Ref.ID 102144]

20.

Khan Q, Ismail M, Haider I, Haq IU, Noor S. QT interval prolongation in hospitalized patients on cardiology wards: a prospective observational study. Eur J Clin Pharmacol 2017;73:1511-8. [Ref.ID 102127]